The Neurofibromatosis 2 Epidemiology report covers the descriptive overview of Hemophilia A, explaining its facts, and symptoms

The Neurofibromatosis 2 Epidemiology report covers the descriptive overview of Hemophilia A, explaining its facts, and symptoms


Neurofibromatosis 2Epidemiology” report has been recently added to DelveInsight


About Neurofibromatosis 2

Neurofibromatosis 2 (NF2) is a rare genetic disorder that is primarily characterized by noncancerous (benign) tumors of the nerves that transmit balance and sound impulses from the inner ears to the brain (bilateral acoustic neuromas/vestibular schwannomas).


Request for free sample copy of Neurofibromatosis 2 epidemiology report-


Neurofibromatosis 2 Epidemiology

DelveInsight’s ‘Neurofibromatosis 2 – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Neurofibromatosis 2 epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.


Neurofibromatosis 2 Symptoms

The characteristic symptoms of NF2 usually develop around the time of puberty or during early adulthood. These symptoms may include problems with balance, buzzing or ringing in the ears (tinnitus), and/or gradual hearing loss. These symptoms usually result from the presence of benign tumors on both auditory nerves (acoustic neuromas vestibular schwannomas). Other tumors of the central nervous system may also develop, and can include neurofibromas, meningiomas, low grade gliomas (mainly benign ependymomas of the spinal cord), and schwannomas. The size, location, and number of tumors may vary in different people affected.


Neurofibromatosis 2 Causes

NF2 is caused by a mutation in the NF2 gene. The NF2 gene regulates (encodes for) the production of a protein known as merlin/schwannomin that plays a role in suppressing the development of certain tumors (tumor suppressor). According to investigators, merlin/schwannomin is related to a class of proteins (ezrin-radixin-moesin proteins) that serve to link the internal, supportive system within a cell (cytoskeleton) to proteins in cell membranes. Several different mutations of the NF2 gene have been identified in individuals with the disorder (e.g., deletions, nonsense and frameshift mutations).


Neurofibromatosis 2 Diagnosis

The diagnosis of NF2 is confirmed by a thorough clinical evaluation and specialized testing (i.e., CT scan, magnetic resonance imaging (MRI), pneumoencephalogram, or arteriogram are very rarely used nowadays). Molecular genetic testing for mutations in the NF2 gene is available for most affected individuals who have a positive family history.


Neurofibromatosis 2 Treatment

The treatment of vestibular (acoustic) neuromas associated with NF2 is the surgical removal of the tumors, when possible. The surgical procedure that is performed is based upon the size and precise location of the tumors. Radiation therapy may be considered for some individuals with this disorder, especially those who are not candidates for surgery. The VEGF inhibitor bevacizumab may also be considered to treat rapidly growing schwannomas but is very expensive.


Neurofibromatosis 2 Epidemiology: Report Scope

  • The Neurofibromatosis 2 report covers a detailed overview explaining its causes, symptoms, and classification, pathophysiology, diagnosis and treatment patterns
  • The Neurofibromatosis 2 Epidemiology Report and Model provide an overview of the risk factors and global trends of Neurofibromatosis 2 in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Neurofibromatosis 2 in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Neurofibromatosis 2
  • The report provides the segmentation of the Neurofibromatosis 2 epidemiology


Request for free sample copy of Neurofibromatosis 2 epidemiology report-


Following is the table of content of Neurofibromatosis 2 epidemiology report

1. Key Insights 

2. Executive Summary of Neurofibromatosis 2

3. Neurofibromatosis 2: Disease Background and Overview

4. Patient Journey

5. Epidemiology and Patient Population

6. Treatment Algorithm, Current Treatment, and Medical Practices

7. KOL Views

8. Unmet Needs

9.  Appendix

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight


What are the important reasons to buy this report?

  • Develop business strategies by understanding the trends shaping and driving the global Neurofibromatosis 2 market
  • Quantify patient populations in the global Neurofibromatosis 2 market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Neurofibromatosis 2 therapeutics in each of the markets covered
  • Understand the magnitude of Neurofibromatosis 2 population by its epidemiology
  • The Neurofibromatosis 2 Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources


Related Reports

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States